BITRF Stock Chart & Stats
$0.04
$0.04(1975.00%)
At close: 4:00 PM EDT
$0.04
$0.04(1975.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.04
Previous CloseN/A
Volume8.20K
Average Volume (3M)7.01K
Market Cap
$3.92M
Enterprise Value$6.55M
Total Cash (Recent Filing)$1.64M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta22.11
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,785,205,000
10 Day Avg. Volume226
30 Day Avg. Volume7,015
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.13
Price to Sales (P/S)0.00
P/FCF Ratio-3.50
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue-7.55K
Enterprise Value/Gross Profit-3.97K
Enterprise Value/Ebitda-3.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces interest and refinancing pressure, preserving financial flexibility while the company funds antiviral development. This provides some protection against solvency stress, although it does not offset the need to improve earnings and cash generation.
Improved CapitalizationThe improvement in equity and asset levels strengthens the balance sheet relative to the prior year and may provide a better base for continued research investment. However, historical instability and negative returns show that capital has not yet produced sustainable profits.
Focused Antiviral R&D PlatformA focused antiviral strategy gives Biotron a clear scientific direction and exposure to healthcare needs that can persist over multiple years. The model could create substantial value if candidates progress, though the pack provides no evidence of current commercial validation.
Bears Say
Persistent LossesRecurring net losses indicate that the business has not established a sustainable earnings model. Continued deficits can constrain research investment, weaken equity over time, and increase dependence on external capital until products generate meaningful revenue.
Ongoing Cash BurnPersistent operating and free-cash-flow deficits mean internal resources are insufficient to fund the business sustainably. This raises ongoing financing risk and could dilute shareholders or force development priorities to change before operations improve.
Revenue InstabilityRevenue volatility and the 2026 collapse to zero leave limited visibility into the company’s commercial scale. Without dependable recurring or milestone revenue, funding research remains difficult and the path to operating breakeven is uncertain.
Biotron News
BITRF FAQ
What was Biotron Limited’s price range in the past 12 months?
Biotron Limited lowest stock price was $0.01 and its highest was $0.04 in the past 12 months.
What is Biotron Limited’s market cap?
Biotron Limited’s market cap is $3.92M.
When is Biotron Limited’s upcoming earnings report date?
Biotron Limited’s upcoming earnings report date is Mar 04, 2027 which is in 131 days.
How were Biotron Limited’s earnings last quarter?
Biotron Limited released its earnings results on Aug 21, 2026. The company reported $0 earnings per share for the quarter.
Is Biotron Limited overvalued?
According to Wall Street analysts Biotron Limited’s price is currently Overvalued.
Does Biotron Limited pay dividends?
Biotron Limited does not currently pay dividends.
What is Biotron Limited’s EPS estimate?
Biotron Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotron Limited have?
Biotron Limited has 2,785,205,000 shares outstanding.
What happened to Biotron Limited’s price movement after its last earnings report?
Biotron Limited reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biotron Limited?
Currently, no hedge funds are holding shares in BITRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biotron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
BITRF Sentiment 75%
Sector Average 66%
Sector Average 66%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Fundamentals
Return on Equity
-54.03%
Trailing 12-Months
Asset Growth
303.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biotron Limited
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
Technical Analysis
Starpharma Holdings Limited
―
Immuron Limited
―
Bio-Gene Technology Ltd.
―
Biome Australia Ltd
―
Recce Pharmaceuticals Ltd.
―